News

Public · Published

enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study

enVVeno Medical reported third quarter 2026 financial results and said cash and investments were $18.5 million at quarter end. The company is on track to begin Part 1 of the FDA-approved TAVVE pivotal study of its enVVe non-surgical replacement venous valve before year end.

Published:

Updated:

What happened

enVVeno Medical reported third quarter 2026 financial results and said cash and investments were $18.5 million at quarter end. The company is on track to begin Part 1 of the FDA-approved TAVVE pivotal study of its enVVe non-surgical replacement venous valve before year end.

Confirmed

Global impact / market context

The $18.5 million in cash and investments is expected to fund operations into the fourth quarter of 2027, covering the planned study start. That means the company should not need to raise more money soon, reducing the risk of selling new shares and diluting existing investors before key safety data arrive.

Analyst inference

enVVeno is a medical device company spending about $3 million per quarter while it runs a U.S. study of a first-in-class device, which means a new type of treatment. Investors are weighing the cash runway against trial timing, since delays in enrolling the first patients could pull forward the need for new funding.

Analyst inference

What to watch

  1. Part 1 of the TAVVE pivotal study will include up to 10 patients who are first monitored for safety, and the company says it is on schedule to enroll its first patient before the end of the year. Confirmed
  2. Watch whether the company activates enough clinical sites to enroll the first patient before year end, since management said sites for Part 1 are being activated and coming online. Proposed
  3. Track the quarterly cash burn near $3 million and any change to the runway into late 2027, because faster spending would shorten the time before the company may need to raise more money. Analyst inference

Evidence